CD276 and neoplasm: In combining OV-CXCL11 therapy with B7-H3-CAR-T, the authors were able to simultaneously combat two main challenges of CAR T therapy against GBM—the immunosuppressive TME and insufficient infiltration of T-cells into the tumor site (Table 2).